Israel'sTeva beats expectations with 40% leap in profit - The Pharma Letter
Proactive Investors USA & CanadaIsrael'sTeva beats expectations with 40% leap in profitThe Pharma LetterProducts launched included escitalopram, modafinil, progesterone, irbesartan and irbesartan/HCTZ, quetiapine and olanzapine ODT.
Product launches, Cephalon acquisition drive Teva's Q1 revenues - Drug Store News
Product launches, Cephalon acquisition drive Teva's Q1 revenuesDrug Store News.
Strong Q1 for Sanofi ahead of challenging nine months - PMLiVE
The Star-Ledger - NJ.
Generic Plavix debuts in US - PMLiVE
Generic Plavix debuts in USPMLiVESanofi and BMS are weathering the impact of two major patent expiries each, with BMS set to lose US patent protection for $1.
Sanofi's strong 1st-qtr driven by Genzyme - The Pharma Letter
Sanofi's strong 1st-qtr driven by GenzymeThe Pharma Letter.